The recent advent of immuno-oncology is changing the research focus and treatment of lung cancers*, highlighting a need for ongoing rapid clinical insights that can be provided via real-world evidence.
Lung cancer (including tracheal and bronchial cancer) is the leading cause of cancer mortality worldwide.1 Significant advances in the understanding of the complexity of lung tumour biology have resulted in the development of novel therapeutic agents evolving beyond chemotherapy for patients who meet appropriate criteria (eg, targeted drugs). Recently, the advent of immuno-oncology (I-O) has resulted in a paradigm shift in the treatment of lung cancers*.
There are a range of treatment options available (eg, chemotherapy, targeted drugs and I-O therapy) for the care of patients. Oncologists and other healthcare professionals require evidence to support informed therapy selection, while payers and regulators require evidence that supports the value of innovative therapies. The change in the treatment landscape highlights the need for ongoing insights that deliver comprehensive clinical and economic data.
Real-world databases†, if maintained and kept up to date, are a ready source of data that can be explored in order to provide stakeholders with additional insights that may complement clinical trial data.
By partnering with healthcare systems across major countries to optimise existing data sources, I-O Optimise will generate timely, ongoing and complementary insights on the evolving lung cancers* landscape to deliver value to oncologists and other healthcare professionals, patients, academic researchers, payers and regulators.